US Patent

US9549926 — Compositions and methods of treating pulmonary hypertension

Method of Use · Assigned to Gilead Sciences Inc · Expires 2031-10-14 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations containing ambrisentan and tadalafil for treating and/or preventing pulmonary hypertension.

USPTO Abstract

Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.

Drugs covered by this patent

Letairis (AMBRISENTAN) · Gilead Sciences

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1965`	—	Letairis
`U-1965`	—	Letairis

Patent Metadata

Patent number: US9549926
Jurisdiction: US
Classification: Method of Use
Expires: 2031-10-14
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.